Cabometyx (cabozantinib) demonstrates real-world survival benefit in advanced renal cell carcinoma

• The study analysed outcomes of adults who were diagnosed with stage III or IV RCC between January 1, 2011 and December 31, 2018, with follow-up lasting until January 31, 2020. A total of 440 patients received cabozantinib treatment, while 1045 received axitinib
• Cabozantinib produced longer survival outcomes than axitinib in patients with advanced RCC that had been previously treated with anti-VEGF agents, according to real-world data presented at the 2021 European Society for Medical Oncology Congress (ESMO)
• Patients treated with cabozantinib had longer median overall survival (OS) than patients treated with axitinib, median OS for cabozantinib treated patients was 11.4 months compared with 9.6 months in axitinib treated patients

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: OCT2021BR002